Open | - |
Close | - |
Volume / Avg. | 0 / 16.067K |
Day Range | - - - |
52 Wk Range | 15.250 - 29.300 |
Market Cap | $583.684M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 50 |
Short Interest | % |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Calliditas Therapeutics (NASDAQ: CALT) through any online brokerage.
Other companies in Calliditas Therapeutics’s space includes: Theravance Biopharma (NASDAQ:TBPH), GH Research (NASDAQ:GHRS), WAVE Life Sciences (NASDAQ:WVE), Tarsus Pharmaceuticals (NASDAQ:TARS) and Phibro Animal Health (NASDAQ:PAHC).
The latest price target for Calliditas Therapeutics (NASDAQ: CALT) was reported by HC Wainwright & Co. on Thursday, February 22, 2024. The analyst firm set a price target for 50.00 expecting CALT to rise to within 12 months (a possible 129.89% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Calliditas Therapeutics (NASDAQ: CALT) is $21.75 last updated March 18, 2024 at 8:18 AM EDT.
There are no upcoming dividends for Calliditas Therapeutics.
Calliditas Therapeutics’s Q1 earnings are confirmed for Tuesday, May 14, 2024.
There is no upcoming split for Calliditas Therapeutics.
Calliditas Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.